AMG 595 / AbbVie - LARVOL DELTA

AMG 595 First-in-Human in Recurrent Gliomas (clinicaltrials.gov) - P1; N=32; Active, not recruiting; Sponsor: Amgen; Recruiting -> Active, not recruiting ; N=60 -> 32

Enrollment change • Enrollment closed • Biosimilar • Oncology

Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII. (PubMed, Cancer Chemother Pharmacol) - "AMG 595 exhibited favorable pharmacokinetics and is a unique therapy with possible benefit for some patients with EGFRvIII-mutated GBM with limited therapeutic options."

Clinical • Journal • PK/PD data • Brain Cancer • CNS Tumor • Fatigue • Glioblastoma • Glioma • Hematological Disorders • Oncology • Solid Tumor • Thrombocytopenia